Tonix Pharma Announces FDA’s Conditional Acceptance of Tonmya™

Tonix Pharma (TNXP) has released an update to notify the public and investors about a regulation fd disclosure.

Tonix Pharmaceuticals Holding Corp. announced the FDA’s conditional acceptance of the trade name Tonmya™ for their TNX-102 SL, a product candidate aimed at managing fibromyalgia. The announcement was made through a press release, which, along with the associated details, is not considered “filed” under the United States Securities Exchange Act of 1934 and does not carry the associated liabilities.

For further insights into TNXP stock, check out TipRanks’ Stock Analysis page.